Key result
Methylene blue may contribute to the improvement of refractory hypotension in vasoplegic syndrome, a complication of cardiopulmonary bypass with an incidence of 5 to 25%.
Why the study?
Does methylene blue improve refractory hypotension in patients with vasoplegic syndrome during cardiac surgery?
Does methylene blue improve refractory hypotension in patients with vasoplegic syndrome during cardiac surgery?
Methylene blue represents a potential therapeutic option for managing refractory hypotension in vasoplegic syndrome following cardiopulmonary bypass.
May support methylene blue for refractory vasoplegia post-bypass; leaves open efficacy and safety confirmation in randomized trials.
Vasoplegic syndrome is a common complication of cardiopulmonary bypass, appearing with an incidence ranging between 5 and 25%. It is characterized by significant hypotension, high or normal cardiac output and low systemic vascular resistance. This syndrome is hypothesized to be caused by the inflammation-mediated dysregulation of endothelial homeostasis and subsequent endothelial dysfunction. In vasoplegic syndrome, the inhibition of the nitric oxide/cyclic guanosine monophosphate pathway with concomitant administration with traditional ionotropes may represent a promising therapeutic option. Methylene blue, an inhibitor of nitric oxide synthase and guanylate cyclase, may contribute to the improvement of refractory hypotension associated with endothelial dysfunction in vasoplegia. In this article, we will update evidence on the potential therapeutic use of methylene blue in vasoplegic syndrome.
No takes yet. Share an insight, caveat, or question.
Lenglet et al. (2011) conducted a review in Vasoplegic syndrome. Methylene blue was evaluated. Methylene blue may contribute to the improvement of refractory hypotension in vasoplegic syndrome, a complication of cardiopulmonary bypass with an incidence of 5 to 25%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: